SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the Thomas Weisel Healthcare Conference in Boston on Wednesday, September 3, 2008 at 9:10 a.m. ET, at the BioCentury NewsMakers Conference in New York on Thursday, September 4, 2008 at 11:30 a.m. ET, and at the Morgan Stanley Global Healthcare Unplugged Conference in New York on Tuesday, September 9, 2008 at 10:55 a.m. ET. Mark G. Foletta, Amylin's Senior Vice President of Finance and Chief Financial Officer, will be providing corporate overviews at Thomas Weisel and BioCentury. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will be providing a corporate overview at Morgan Stanley.
The live presentations will be Web cast, and recordings will be made available following the event. The Web casts and recordings will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live Web casts, please log on to Amylin's site approximately fifteen minutes prior to the presentations to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.
CONTACT: Michael York, Senior Director, Investor Relations of Amylin
Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602
Web site: http://www.amylin.com/
